Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index - Top-Institutions - MDSpire

Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index

  • By

  • Koji Jimbo

  • Ayumu Ito

  • Hirona Ichimura

  • Junichi Kuroda

  • Shohei Andoh

  • Aki Sato

  • Kazuaki Yokoyama

  • Takahiro Fukuda

  • Kaoru Uchimaru

  • Yasuhito Nannya

  • October 16, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Hematology
    • Oncology
    • Lymphoma Research

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology
    • Bone Marrow Transplantation

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, Washington

    Key Differentiators

    • Hematology
    • Bone Marrow Transplantation
    • Immunology

  • #4

    Kyoto University Hospital
    Kyoto University Hospital

    Kyoto, Kyoto

    Key Differentiators

    • Hematology
    • Oncology
    • Virology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology
    • Lymphoma Research

Original Source(s)

Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index

  • by Koji Jimbo, Ayumu Ito, Hirona Ichimura, Junichi Kuroda, Shohei Andoh, Aki Sato, Kazuaki Yokoyama, Takahiro Fukuda, Kaoru Uchimaru, Yasuhito Nannya

  • October 16, 2025

Related Content

Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies

A study found that outpatient observation cut hospital stays dramatically, with no adverse safety events reported. It also freed up inpatient beds and cut healthcare costs.

  • by

  • January 9, 2026

  • 4 min
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders